AMENDED FULL PROPOSAL - OCT 12TO BENCHMARK THE UTILITY OF E06: HALF LIFE EXTENSION, SINGLE DOMAIN, SHARK ANTIBODY BIO-TOOL, AND PROGRESS IT TO PHASE 1 READY CANDIDATE CLONE

Medicine & Life Sciences

1. Sharks 100%
2. Adalimumab 84%
3. Antigen Receptors 74%
4. In Vitro Techniques 35%
5. Uveitis 33%
6. Transgenic Mice 29%
7. Arthritis 28%
8. Drug Development 28%
9. Clone Cells 27%
10. Autoimmune Diseases 26%
11. Lead 21%
12. Tumor Necrosis Factor-alpha 21%
13. Ligands 21%
14. Enzyme-Linked Immunosorbent Assay 21%
15. Biological Products 21%
16. Therapeutics 18%
17. Human Serum Albumin 17%
18. Half-Life 17%
19. Serum 16%
20. Pharmaceutical Preparations 15%
21. Anti-Idiotypic Antibodies 13%
22. Antigens 11%
23. Nurses 10%
24. Bacteriophages 9%
25. Immunoglobulins 9%
26. Libraries 8%
27. Inflammation 8%
28. Inducible T-Cell Co-Stimulator Protein 8%
29. interstitial retinol-binding protein 8%
30. Mutagenesis 7%
31. Chronic Disease 6%
32. Dendritic Cells 6%
33. Biological Factors 6%
34. T-Lymphocytes 6%
35. Electric Impedance 6%
36. Life Expectancy 5%
37. Psoriasis 5%
38. Inflammatory Bowel Diseases 5%
39. Antibodies 5%
40. Biological Assay 5%